Caricamento...
NCMP-05. RITUXIMAB AS INITIAL THERAPY FOR THE REVERSAL OF MYASTHENIA GRAVIS NEUROTOXICITY CAUSED BY IPILIMUMAB/NIVOLUMAB
BACKGROUND: In patients with melanoma treated with immune checkpoint inhibitors (ICIs), neurological toxicities developed in 1% treated with Ipilimumab and 3% after Nivolumab. This rises to 14% when co-administered. Patients treated with ICIs are susceptible to Myasthenia Gravis like syndrome. There...
Salvato in:
| Pubblicato in: | Neuro Oncol |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Oxford University Press
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6216679/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.806 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|